What are the costs, capacity, and clinical implications of 'waiting for documented progression' in young West of Scotland patients prior to collagen cross linking?

Simpson, Alasdair; Brogan, Kerr; Ramaesh, Kanna; Lockington, David

Simpson, Alasdair; Brogan, Kerr; Ramaesh, Kanna; Lockington, David.

Simpson A; Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, United Kingdom.
Brogan K; Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, United Kingdom.
Ramaesh K; Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, United Kingdom.
Lockington D; Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, United Kingdom. davidlockington@hotmail.com.

Eye (Lond) ; 35(7): 1808-1810, 2021 07.

Article in English | MEDLINE | ID: covidwho-1428807

Subject(s)

Collagen; Keratoconus; Cross-Linking Reagents; Humans; Photosensitizing Agents; Riboflavin; Scotland/epidemiology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Collagen / Keratoconus Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: Eye (Lond) Journal subject: Ophthalmology Year: 2021 Document Type: Article Affiliation country: S41433-021-01444-x

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google